Europe Neoantigens Market to Grow at a CAGR of 31.7% to reach US$ 341,855.35 thousand from 2021 to 2028

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Neoantigens Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Neoantigens Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Biotechnology developments increasing
5.1.3 Cancer driving personalized immunotherapies
5.1.4 Advances in genomic sequencing enhancing therapies
5.1.5

5.2 Market Opportunities

5.2.1
5.2.2 Expansion of collaborations between biotech firms and academic institutions for neoantigen discovery and validation.
5.2.3 Rising interest in neoantigen vaccines and therapeutic approaches as adjuncts to existing cancer treatments.
5.2.4 Potential for application in autoimmune diseases and other therapeutic areas leveraging neoantigen targeting.

5.3 Future Trends

5.3.1
5.3.2 Development of AI and machine learning tools for more efficient neoantigen prediction and identification.
5.3.3 Increasing use of combination therapies incorporating neoantigens with checkpoint inhibitors for enhanced efficacy.
5.3.4 Advancements in personalized vaccine platforms using neoantigens to boost immune responses in cancer patients.

5.4 Impact of Drivers and Restraints

6. Europe Neoantigens Market Regional Analysis

6.1 Europe Neoantigens Market Overview

6.2 Europe Neoantigens Market Revenue 2021-2028 (US$ Thousand)

6.3 Europe Neoantigens Market Forecast Analysis

7. Europe Neoantigens Market Analysis – by Treatment

7.1 Combination Therapy and Mono Therapy

7.1.1 Overview
7.1.2 Combination Therapy and Mono Therapy: Europe Neoantigens Market – Revenue and Forecast to 2031 (US$ Thousand)

8. Europe Neoantigens Market Analysis – by Therapeutic Specialty

8.1 Gastrointestinal Cancer

8.1.1 Overview
8.1.2 Gastrointestinal Cancer: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

8.2 Lung Cancer

8.2.1 Overview
8.2.2 Lung Cancer: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

8.3 Solid Tumor

8.3.1 Overview
8.3.2 Solid Tumor: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

8.4 Urinary Systems Cancers

8.4.1 Overview
8.4.2 Urinary Systems Cancers: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

8.5 Melanoma

8.5.1 Overview
8.5.2 Melanoma: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

8.6 Head and Neck Cancer

8.6.1 Overview
8.6.2 Head and Neck Cancer: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9. Europe Neoantigens Market – Europe Analysis

9.1 Europe

9.1.1 Europe Neoantigens Market Breakdown, by Key Country, 2024 and 2028 (%)
9.1.1.1 Europe Neoantigens Market – Revenue and Forecast Analysis – by Country
9.1.1.1 UK: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.1.1.1.1 UK: Europe Neoantigens Market Breakdown, by Treatment
9.1.1.1.2 UK: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.1.1.2 Germany: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.1.1.2.1 Germany: Europe Neoantigens Market Breakdown, by Treatment
9.1.1.2.2 Germany: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.1.1.3 France: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.1.1.3.1 France: Europe Neoantigens Market Breakdown, by Treatment
9.1.1.3.2 France: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.1.1.4 Russia: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.1.1.4.1 Russia: Europe Neoantigens Market Breakdown, by Treatment
9.1.1.4.2 Russia: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.1.1.5 Italy: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.1.1.5.1 Italy: Europe Neoantigens Market Breakdown, by Treatment
9.1.1.5.2 Italy: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

9.1.1.6 Rest of Europe: Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

9.1.1.6.1 Rest of Europe: Europe Neoantigens Market Breakdown, by Treatment
9.1.1.6.2 Rest of Europe: Europe Neoantigens Market Breakdown, by Therapeutic Specialty

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Europe Neoantigens Market Industry Landscape

11.1 Overview

11.2 Mergers and Acquisitions

11.3 Agreements, Collaborations, and Joint Ventures

11.4 New Product Launches

11.5 Expansions and Other Strategic Developments

12. Company Profiles

12.1 Achilles Therapeutics plc

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Frame Cancer Therapeutics

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 Genocea

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 Immunicum AB

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Medigene AG

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Moderna, Inc

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

13. Appendix

13.1 About Business Market Insights